MAPT and Alzheimer disease: This might have implications for clinical trials, since drugs reducing soluble p-tau concentrations (like anti-Aβ therapies or genetic anti-tau treatments) may be promising therapeutic strategies to prevent further accumulation and spread of tau aggregates and cognitive decline in early stages of AD.